|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions显示文摘AIM To investigate the main current etiologies of cirrhosis in Mexico.METHODS We performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period(January 2012-December 2017). RESULTS A total of 1210 patients were included. The mean age was 62.5 years(SD = 12.1), and the percentages of men and women were similar(52.0% vs 48.0%). The most frequent causes of liver cirrhosis were hepatitis C virus(HCV)(36.2%), alcoholic liver disease(ALD)(31.2%), and nonalcoholic steatohepatitis(23.2%), and the least frequent were hepatitis B virus(1.1%), autoimmune disorders(7.3%), and other conditions(1.0%).CONCLUSION HCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease(NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico. | Nahum Méndez-Sánchez Felipe Zamarripa-Dorsey Arturo Panduro Emma Purón-González Edgar Ulises Coronado-Alejandro Carlos Alejandro Cortez-Hernández Fátima Higuera de la Tijera José Luis Pérez-Hernández Eira Cerda-Reyes Heriberto Rodríguez-Hernández Vania César Cruz-Ramón Oscar Lenin Ramírez-Pérez Nancy Edith Aguilar-Olivos Olga Fabiola Rodríguez-Martínez Samantha Cabrera-Palma Guillermo Cabrera-álvarez | 2018 | World Journal of Clinical Cases2018，6，15： | 2 |
| 2 | Climate-induced boreal forest change: Predictions versus current observations显示文摘 | Amber J S Nadezda M T Nancy H F | 2007 | Global and Planetary Change2007，56，： | 1 |
| 3 | Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial显示文摘 | Edward J Gane Stuart K Roberts Catherine AM Stedman Peter W Angus Brett Ritchie Rob Elston David Ipe Peter N Morcos Linda Baher Isabel Najera Tom Chu Uri Lopatin M Michelle Berrey William Bradford Mark Laughlin Nancy S Shulman Patrick F Smith | 2010 | The Lancet2010，，9751： | 1 |
| 4 | Osteopontin expression in lung cancer显示文摘 | SYLVIA M W NANCY K | 1996 | Lung Cancer1996，15，： | 1 |
| 5 | Determination of cercosporin (CER) phytotoxin isolated from infected peanut leaves by using adsorptive stripping square wave voltammetry 显示文摘 | Nancy C M Maria A Z Hector F | 2005 | Analytica Chimica Acta2005，550，： | 1 |
| 6 | Mutations in the heparin-binding domains of human basic fibroblast growth factor alter its biological activity 显示文摘 | William F H Amanda SC Nancy G M | 1991 | Biochemistry1991，30，22： | 1 |
| 7 | Composition of gestational weight gain impacts maternal fat retention and infant birth weight显示文摘 | Nancy F Butte Kenneth J Ellis William W Wong Judy M Hopkinson E.O’Brian Smith | 2003 | American Journal of Obstetrics and Gynecology2003，，： | 1 |
| 8 | Modafinil in the treatment of excessive daytime sleepiness显示文摘 | Valentino R M Nancy F S | 2007 | Cleveland Clinic Journal of Medicine2007，74，8： | 1 |
| 9 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 10 | Does assisted hatching pose a risk for monozygotic twinning in pregnancies conceived through in vitro fertilization?显示文摘 | Laura A Schieve Susan F Meikle Herbert B Peterson Gary Jeng Nancy M Burnett Lynne S Wilcox | 2000 | Fertility and Sterility2000，，2： | 1 |
| 11 | Iron-Chelating Therapy and the Treatment of Thalassemia显示文摘 | Nancy F Olivieri Gary M | 1997 | Blood1997，89，3： | 1 |
| 12 | Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and muhidrug-resistant ovarian and peritoneal carcinoma显示文摘 | Peter GR Kim M Nancy F | 2003 | Gynecol Oncol2003，88，1： | 1 |
| 13 | PDMS oe cluded Ti-MCM-41 as an improved olefin epoxidationcatalyst显示文摘 | Vankelecom J F Nancy M F Karen A L | 1997 | Studies in Surface Science and Catalysis1997，108，： | 1 |
| 14 | Psychiatric illness in patients with end-stage renal disease显示文摘 | Paul L Kimmel Mae Thamer Christian M Richard Nancy F Ray | 1998 | The American Journal of Medicine1998，，3： | 1 |
| 15 | Central nervous system disease in patients with systemic lupupus erythematosus显示文摘 | Lonni RS Clark M | 1992 | Neurology1992，42，8： | 1 |
| 16 | A raft- ware package to teach FEA Concepts显示文摘 | Nancy M Abe Jose R Cardom Douglas R F Clabunde | 1997 | IEEE Transactions on Magnetics1997，33，2： | 1 |
| 17 | Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level显示文摘 | Ken C Chiu Lee-Ming Chuang Nancy P Lee Jennifer M Ryu Jennifer L McGullam George P Tsai Mohammad F Saad | 2000 | Metabolism2000，，11： | 1 |
| 18 | Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras显示文摘 | Nancy F Crum Robert H Riffenburgh Scott Wegner Brian K Agan Sybil A Tasker Katherine M Spooner Adam W Armstrong Susan Fraser Mark R Wallace | 2006 | JAIDS Journal of Acquired Immune Deficiency Syndromes2006，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员